BEIJING, July 14, 2014 /PRNewswire/ — General Steel Holdings, Inc. (“General Steel” or the “Company”) (NYSE: GSI), a leading non-state-owned steel producer in China, today announced that the Company has entered into a definitive Subscription Agreement…
BEIJING, July 12, 2014 /PRNewswire/ — Rabobank, the Dutch multinational banking and financial services company, issued the latest 2014 Global Dairy Top 20 Report on July 9, 2014, in which China-based Inner Mongolia Yili Industrial Group Co., Ltd. (Yil…
SINGAPORE, July 11, 2014 /PRNewswire/ — Asia Plantation Capital has been developing sustainable, organic, Patchouli oil production on its plantations for the last year. Patchouli oil is extracted from the leaves of the perennial patchouli bush (which regrows) allowing the leaves to be harvested, sustainably, every 3 to 4 months.
The recent harvest and production of Patchouli oil, by Asia Plantation Capital, on its plantations in Sri Lanka has been certified as premium grade by independent analysts at the Industrial Technology Institute (ITI), Colombo.
When analysed via mass spectrometry by the ITI, samples of our oil tested positive for the major compounds of Patchouli oil.
Of these compounds, Patchouli alcohol is the main constituent which determines the quality of the oil. Consequently, the price of the Patchouli oil strongly depends on the ratio of Patchouli alcohol present in the oil.
Spectrometry results clearly indicate the high content of patchouli oil (0.53%) and patchouli alcohol (54.56%) in the oil sample which was taken after the distillation process. A patchouli alcohol content of over 30% is considered excellent quality.
These results show that the cultivation of patchouli for commercial oil extraction in Sri Lanka is a viable proposition.
This is a significant breakthrough for Asia Plantation Capital in Sri Lanka. We already cultivate Patchouli in Thailand and are now gearing up to follow our success in the production of high quality Oud oil with large scale production of Patchouli; for Sri Lanka, this can be particularly beneficial as it can create a new, high quality crop to boost exports and the rural economy.
Lalith Ganlath, Attorney for Asia Plantation Capital in Colombo, says, “It’s a pleasure to see the hard work of the Sri Lankan, Asia Plantation Capital team paying off in Sri Lanka, on the back of plantation projects which the Company operates in other parts of South East Asia, and helping to contribute research and innovation to the country’s agricultural export markets. I am very keen to help promote this project and encourage out-growers to cultivate the Patchouli, which can become part of their existing agroforestry incomes. It will also help maximise land use and returns for rural farmers, with Asia Plantation Capital agreeing to buy back the dry leaves which can be harvested every 3 months.”
Asia Plantation Capital already has its own distribution offices, retail shops and warehouses in the Middle East, Europe, Asia and the USA, supplying the industry. It is well set to become a major supplier of sustainable Patchouli oil, traceable to the source of production — Patchouli oil is one of the most widely used oils in the international Fragrance industry and has a forecast industry value of over $46 billion in 2018 (Source: Industry Analyst’s Inc.). Interestingly, Patchouli oil is one of the few natural essential oils which cannot be reproduced in any high quality, synthetically, for use in perfumes; making the demand for this excellent oil relatively assured.
Over the next year, the Company aims to establish over 5,000 acres of Patchouli fields using a combination of their own lands in South East Asia and out grower schemes in Sri Lanka, Thailand and Malaysia. All production for the plantations will be supplied with Certificate of Origin, Certificate of Analysis (CofA), Material Safety Data Sheet (MSDS) for exports and Flow of Processing and Product Specification. In addition, the oil will be packaged under the Group’s perfume brand, “Fragrance Du Bois” and branded, “Patchouli Du Bois” as a further stamp of guaranteed quality — which has been a key to the success in globally marketing the Company’s other essential oils such as Oud (agarwood) and also infected wood chips.
Asia Plantation Capital Pte. Ltd. 50 Collyer Quay, #06-05 OUE Bayfront, Singapore 049321
Tel: +65 6222 3386 | Fax: +65 6221 2197 | Email: email@example.com
ABBOTT PARK, Ill. and AUCKLAND, New Zealand, July 11, 2014 /PRNewswire/ — Abbott (NYSE: ABT) and Fonterra Co-operative Group Ltd today announced the signing of an agreement to develop a proposed dairy farm hub in China. The strategic alliance, which is subject to Chinese regulatory approval, will leverage Fonterra’s expertise in dairy nutrition and farming in China and Abbott’s continued commitment to business development in China.
Dairy consumption in China has been rising steadily over the past 10 years. The continued development of safe, high-quality milk sources is essential to meeting this growing demand from Chinese consumers. Abbott and Fonterra are pleased to be able to work together and, through this alliance, make a positive contribution to the growth and development of China’s dairy industry.
“This would be Fonterra’s third farm hub in China and will complement our existing farming operations in Shanxi and Hebei Provinces that have been very successful,” said Theo Spierings, chief executive, Fonterra. “Farming hubs are a key part of our strategy to be a more integrated dairy business in Greater China, contribute to the growth and development of the local Chinese dairy industry, and help meet local consumers’ needs for safe, nutritious dairy products.”
“We’re pleased to partner with Fonterra, a global leader in dairy science, on this alliance to build dairy capacity in China,” said Miles D. White, chairman and chief executive officer, Abbott. “This is a very important step in our growing commitment to Chinese consumers.”
Both companies will work with Chinese regulators to obtain necessary approvals through the course of the project’s development.
If approved, Abbott and Fonterra will form a joint venture to invest a combined US$300 million (NZ$342 million or 1.8 billion RMB) into the farm hub, which will contain up to five dairy farms and more than 16,000 dairy milking cattle in production, producing up to 160 million liters of milk annually. The herd for this hub will comprise animals either imported, or sourced from Fonterra’s existing farm hubs. All dairy cattle will have genetics traceable to New Zealand, Australia, the United States and Europe.
As the world’s largest global milk processor and dairy exporter, Fonterra brings industry-leading dairy standards and practices to farm operations. The Fonterra-Abbott joint venture will operate the farm hub in China to these same standards to produce high-quality dairy.
Pending regulatory approval, the first farm is expected to be completed and producing milk in the first half of 2017 and the remaining farms will commence production in 2018.
Abbott and Fonterra have a long history in China and have made substantial commercial and social investments in the country.
Fonterra is a global leader in dairy nutrition – the preferred supplier of dairy ingredients to many of the world’s leading food companies. Fonterra is also a market leader with our own consumer dairy brands in Australia/New Zealand, Asia/Africa, Middle East and Latin America.
The farmer-owned New Zealand co-operative is the largest processor of milk in the world, producing more than two million tonnes of dairy ingredients, value added dairy ingredients, specialty ingredients and consumer products every year. Drawing on generations of dairy expertise, Fonterra is one of the largest investors in dairy based research and innovation in the world. Our more than 16,000 staff work across the dairy spectrum from advising farmers on sustainable farming and milk production, to ensuring we live up to exacting quality standards and delivering every day on our customer promise in more than 100 markets around the world.
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 69,000 people.
In China, Abbott has more than 4,000 employees working in manufacturing, research and development, logistics, sales and marketing. Primary locations in China are in Shanghai, Beijing and Jiaxing.
ABBOTT PARK, Ill., July 11, 2014 /PRNewswire/ — Today’s announcement of a proposed strategic alliance with Fonterra to develop dairy farms is the latest in a series of investments Abbott (NYSE: ABT) has made in China, deepening its commitment in the country. In June, Abbott opened a state-of-the-art nutritional manufacturing facility in Jiaxing, and earlier this year, Abbott opened two research and development centers in Shanghai. In 2014, Abbott has announced more than US$400 million (2.5 billion RMB) of investments in its China operations.
Abbott has made these investments in order to improve people’s nutrition and health, and further establish the company as a long-term partner in China’s development. Today, Abbott has more than 4,000 employees in China. Abbott investments and engagements in China include:
- Collaboration with the government since 2008 to strengthen nutritional science and testing capabilities, and share technical expertise to promote food safety.
- Operation of a medical optics facility in Hangzhou, a pharmaceutical facility in Shanghai, and new research and development centers for its nutrition and diagnostics businesses in Shanghai.
- Creation of the Abbott Crossroads Institute training center in Shanghai, which educates healthcare providers in coronary, endovascular and structural heart interventions.
- Implementation of innovative initiatives across Abbott’s China manufacturing operations to reduce emissions, water use and waste, and to make product packaging more sustainable.
- Establishment of the Abbott Fund Institute of Nutrition Science (AFINS), in partnership with Shanghai Children’s Medical Center and the global non-profit organization Project HOPE. The partnership, which operated from 2007 through this year, strengthened clinical pediatric nutrition practices, training, research and community outreach.
“Our goal is to help people live healthier lives,” said Miles D. White, chairman and chief executive officer, Abbott. “That means investing in the countries where we live and work. We’re committed to using our science, our product quality and educational efforts to raise the level of health in China and around the world.”
HONG KONG, July 10, 2014 /PRNewswire/ — Anton Oilfield Services Group (“Antonoil” or the “Group”, HKEx stock code: 3337), the leading independent oilfield services provider in China, is pleased to announce that a new Production Operation Service contr…
HONG KONG, July 10, 2014 /PRNewswire/ — The largest and most influential fashion exhibition in southern China, the 14th China International Fashion Brand Fair — Shenzhen (FashionSZshow), opened today in Shenzhen. This annual fashion event is the perf…
SHANGHAI, July 9, 2014 /PRNewswire/ — CSA Group, a global leader in testing and certification services and a standards development organization, inaugurated its first highly specialized testing and certification laboratory in Bangalore, India. The new…
WUXI, China, July 7, 2014 /PRNewswire/ — WSP Holdings Limited (NYSE: WH) (“WSP Holdings” or the “Company”), a Chinese manufacturer of API (“American Petroleum Institute”) and non-API seamless casing, tubing and drill pipes used in oil and natural gas …
ZHEJIANG, China, July 7, 2014 /PRNewswire/ — SORL Auto Parts, Inc. (NASDAQ: SORL) (“SORL” or the “Company”), a leading manufacturer and distributor of automotive brake systems as well as other key safety-related auto parts in China, announced today th…